Skip to content

Factor VII

Published: July 26, 2026Updated: August 20, 2026

Factor VII is a vitamin K-dependent clotting factor essential for the initiation of blood coagulation. It is primarily indicated for the treatment and prevention of bleeding in patients with congenital factor VII deficiency, and may also be used as a bypassing agent in hemophilia patients with inhibitors. The medication is administered via intravenous injection under medical supervision.

Quick summary

Factor VII is a clotting factor medication used to treat bleeding in factor VII deficiency and hemophilia patients with inhibitors.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ATC
B02BD05
RxNorm
4254
Generic
Factor Vii
Class
atc-b02
Brands
Kcentra, Balfaxar
Availability
rx
Lactation
unknown
Routes
—
Forms
injection
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Factor VII is used for the prevention and treatment of bleeding episodes in patients with congenital factor VII deficiency (a rare bleeding disorder). It may also be utilized as a bypassing agent for hemophilia A or B patients with inhibitors who experience bleeding that does not respond to standard therapy.

Factor VII initiates the extrinsic pathway of the coagulation cascade by binding to tissue factor exposed at sites of vascular injury. This complex then activates factor X, which ultimately converts prothrombin to thrombin, leading to fibrin clot formation and hemostasis.

Factor VII should only be administered by healthcare professionals experienced in managing bleeding disorders. Regular monitoring of coagulation parameters is recommended during treatment. Patients should be observed for signs of thrombotic complications. The medication is typically given as intravenous injection, with dosing based on individual patient factors and clinical circumstances.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy